Posted On: 08/26/2015 7:59:16 PM
Post# of 30070
Svan, I agree with your post and will admit GC has turned a fledgling biotech into a company with potential.
However how can a CEO who has over promised and under delivered countless times be upset when the shareholders have finally had enough?
1) Codes for Lympro?
2) Mentioning Partners and only get a service agreement?
3) The AAIC debacle from last July?
4) Money Runners?
5) Relationship with a dirty government official?
6) RUO market of 150 mil for Lympro, 0 to date?
7) 50 K for a silver sponsorship and a rehash of old data?
Uplist from strength possible RS not needed?
9) Authorization of 35 mil shares without guidance?
10) Institutional Investors?
These are just a quick list of why so many are abandoning ship, add that with GC's twitter tantrum blaming shareholders as the icing on the cake and you see the catastrophe we call a PPS.
Time will tell if they pull the rabbit out of the hat but from their track record most have their doubts.
However how can a CEO who has over promised and under delivered countless times be upset when the shareholders have finally had enough?
1) Codes for Lympro?
2) Mentioning Partners and only get a service agreement?
3) The AAIC debacle from last July?
4) Money Runners?
5) Relationship with a dirty government official?
6) RUO market of 150 mil for Lympro, 0 to date?
7) 50 K for a silver sponsorship and a rehash of old data?
Uplist from strength possible RS not needed? 9) Authorization of 35 mil shares without guidance?
10) Institutional Investors?
These are just a quick list of why so many are abandoning ship, add that with GC's twitter tantrum blaming shareholders as the icing on the cake and you see the catastrophe we call a PPS.
Time will tell if they pull the rabbit out of the hat but from their track record most have their doubts.
(0)
(0)
